Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Molecular Classification of Endometrial Carcinoma in the Clinic Today

Listen to Mansoor Raza Mirza, MD, and Ana Oaknin, MD, PhD, discuss the implications of recent advances in the use of molecular testing and classification to guide the treatment of patients with endometrial cancer.

This podcast is intended for clinicians practicing medicine outside of the United States.

person default
Mansoor Raza Mirza, MD
Ana Oaknin, MD, PhD
Released: November 11, 2020

In this episode, Mansoor Raza Mirza, MD, and Ana Oaknin, MD, PhD, discuss the implications of recent advances in the use of molecular testing and classification to guide the use of immunotherapy for the treatment of patients with endometrial cancer.

Presenters:

Ana Oaknin, MD, PhD
Head of Gynecologic Tumors Unit
Medical Oncology Department
Vall d´Hebron University Hospital
Barcelona, Spain 

Mansoor Raza Mirza, MD
Chief Oncologist
Department of Oncology,
Rigshopitalet – Copenhagen University Hospital
Copenhagen, Denmark

Acknowledgements

Supported by an educational grant from
GlaxoSmithKline

Related Content

Slides from Clinical Care Options (CCO) on biomarker testing to guide targeted therapy for gastroesophageal cancers

Manish A. Shah, MD Released: January 21, 2022

Slides from Clinical Care Options (CCO) on biomarker testing to guide targeted therapy for pancreatic and biliary tract cancers

Rachna Shroff, MD Released: January 21, 2022

Slides from Clinical Care Options (CCO) on biomarker testing to guide targeted therapy for colorectal cancer (CRC)

John L. Marshall, MD Released: January 21, 2022

In this commentary from Clinical Care Options (CCO), Asim V. Farooq, MD and Joann Kang, MD, provide guidance on monitoring and mitigating ocular toxicities associated with antibody-drug conjugates

Asim V. Farooq, MD Joann Kang, MD Released: January 20, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings